CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Karen Walton-Bowen, M.Sc., C.Stat, a biostatistician with more than 20 years experience in the pharmaceutical and biotechnology industries, has joined Abt Bio-Pharma Solutions, Inc. (ABS), as Senior Director, Biometrics. An expert in clinical trials and regulatory submissions in all phases of clinical development across multiple therapeutic areas, Ms. Walton-Bowen's experience encompasses clinical operations, data management, programming, statistical support, and medical writing, both in the U.S. and in Europe. In addition to leading ABS' full service Biometrics team, she will work one-on-one with sponsors to provide sophisticated biostatistics and medical writing consulting services for registries and late-phase clinical trials.
"Karen's strong technical and project management skills will make her a 'go to' resource for our small- to medium-size clients who wish to extend their capabilities with direct access to an hands-on expert with broad and deep therapeutic area experience," said Dr. Kay Larholt, Vice President of Biometrics & Clinical Operations. "We also expect Karen to add value and strengthen our already accomplished Biometrics team as it continues to support all our clinical projects, including clinical trials and registries."
Prior to joining ABS, Ms. Walton-Bowen was most recently Senior Director of Clinical Operations, Biostatistical Analysis, and Reporting at Critical Therapeutics, Inc. Previously, she spent four years at Genzyme Corporation, where she led the Biometrics team in a successful BLA submission and FDA Advisory Panel approval of a drug for a rare life-threatening disease in children. Ms. Walton-Bowen also spent many years at Astra (in the US and Sweden) as a biostatistician working on different compounds in the respiratory business unit. During that time she submitted numerous NDAs and represented the company at FDA meetings and Advisory Panels.
Ms. Walton-Bowen was awarded her M.Sc. in Medical Statistics by the University of London and earned her B.S. degree with honors in Mathematics & Computing from South Bank University, London, England. She is a member of the Royal Statistical Society, American Statistical Association, Drug Information Association, and the Association of Clinical Research Professionals. Ms. Walton-Bowen's work has been published in leading journals including Statistics In Medicine, The Journal of Pediatrics, and Annals of Allergy, Asthma & Immunology. She was also a contributor to Biopharmaceutical Sequential Statistical Applications, an important textbook on interim analyses with contributions from industry leaders.
The ABS team has provided integrated strategic, research, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries as well as through retrospective data analyses, models, and quantitative and qualitative research. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, and communicate the results to internal and external audiences. Primary service offerings include biometrics, clinical trials, registries and other late-phase clinical studies, health economics and outcomes research, pricing and reimbursement, and strategic commercialization services. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.
|SOURCE Abt Bio-Pharma Solutions, Inc.|
Copyright©2008 PR Newswire.
All rights reserved